International Stem Cell (ISCO) Stock Price, News & Analysis

Company Overview

International Stem Cell Corporation is a biotechnology company focused on developing human stem cell-based products and therapies. Its research has centered on proprietary parthenogenetic human stem cells, which are derived from unfertilized human oocytes and are intended to provide a potentially useful source of cells for regenerative medicine.

The company has pursued applications in tissue engineering and cell therapy, including programs involving corneal tissue and other specialized cell types. Its development activities have included research into producing differentiated cells from parthenogenetic stem cells for potential use in treating disease and repairing damaged tissue.

International Stem Cell has also operated through subsidiaries and related businesses involved in commercial skincare products. Its Lifeline Skin Care business markets products incorporating human stem cell-derived ingredients, extending the company’s activities beyond therapeutic research into the consumer skincare market.

Key Stats

• Today's Range: $0.30 to $0.33
• 50-Day Range: $0.17 to $0.51
• 52-Week Range: $0.12 to $0.54
• Volume: 3,144 shs
• Average Volume: 19,582 shs
• Market Capitalization: $2.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

International Stem Cell Stock Analysis - MarketRank™

International Stem Cell scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for International Stem Cell.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of International Stem Cell is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of International Stem Cell is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of International Stem Cell has been sold short.

Short Interest Ratio / Days to Cover

International Stem Cell has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in International Stem Cell has recently decreased by 94.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

International Stem Cell does not currently pay a dividend.

Dividend Growth

International Stem Cell does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

International Stem Cell has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for International Stem Cell this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, International Stem Cell insiders have not sold or bought any company stock.

Percentage Held by Insiders

78.05% of the stock of International Stem Cell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

International Stem Cell has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ISCO
• CIK: 1355790
• Web: www.internationalstemcell.com
• Phone: (760) 940-6383
• Fax: 760-476-0600
• Employees: 33
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$420 thousand
• Net Margins: -6.12%
• Pretax Margin: -6.12%
• Return on Equity: N/A
• Return on Assets: -11.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.45

Sales & Book Value

• Annual Sales: $9.10 million
• Price / Sales: 0.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.51) per share
• Price / Book: -0.65

Miscellaneous

• Outstanding Shares: 8,004,000
• Free Float: 1,757,000
• Market Cap: $2.64 million
• Optionable: Not Optionable
• Beta: N/A